Comparative Pharmacology
Head-to-head clinical analysis: FOSAMAX versus PAMIDRONATE DISODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSAMAX versus PAMIDRONATE DISODIUM.
FOSAMAX vs PAMIDRONATE DISODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone matrix and impairing osteoclast activity through inhibition of farnesyl pyrophosphate synthase.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by adsorbing to hydroxyapatite crystals and inhibiting their dissolution, and by inhibiting osteoclast activity via farnesyl pyrophosphate synthase inhibition.
70 mg orally once weekly for osteoporosis; 10 mg orally once daily for Paget's disease.
90 mg intravenously over 2-24 hours every 3-4 weeks for hypercalcemia of malignancy; 60-90 mg intravenously over 2-24 hours every 2-4 weeks for osteolytic bone metastases or Paget disease.
None Documented
None Documented
Terminal elimination half-life is approximately 10.5 years in bone, reflecting slow release from the skeleton. Plasma half-life after intravenous administration is about 1 hour.
Triphasic: terminal elimination half-life (t1/2γ) is 27-28 hours, representing slow release from bone. Clinical context: prolonged suppression of bone resorption persists weeks after serum levels become undetectable.
Renal excretion of unchanged drug is the primary route (approximately 50% of absorbed dose). Unabsorbed drug is eliminated in feces. No biliary excretion.
Primarily renal; 30-62% of unchanged drug excreted in urine within 72 hours, with the remainder bound to bone and slowly released. Biliary/fecal elimination is negligible (<1%).
Category C
Category D/X
Bisphosphonate
Bisphosphonate